Teva Pharmaceutical (TEVA) Fundamental Analysis: Revenue, Earnings & Valuation

1.49 / 10

Underperform

Fundamentally TEVA is rated Underperform with a 1.5/10 strength. Inventory and fixed‑asset turnover are positive, but accounts‑receivable turnover and modest 4.3% revenue growth are concerns. Cost of sales is high and tax‑to‑profit ratio is negative, supporting a defensive view.

Analysis Checks(6/10)

Revenue-MV

Value0.47

Score2/3

Weight40.66%

1M Return6.87%

Total operating revenue (YoY growth rate %)

Value4.32

Score1/3

Weight-5.84%

1M Return-1.40%

Inventory turnover ratio

Value2.69

Score2/3

Weight-3.02%

1M Return-0.66%

Accounts receivable turnover ratio

Value5.10

Score1/3

Weight-6.78%

1M Return-1.57%

PB-ROE

Value-0.18

Score1/3

Weight25.43%

1M Return5.22%

Income tax / Total profit (%)

Value-14.72

Score2/3

Weight16.60%

1M Return3.20%

Fixed assets turnover ratio

Value3.99

Score2/3

Weight-4.30%

1M Return-1.01%

Interest coverage ratio (EBIT / Interest expense) (%)

Value2.34

Score2/3

Weight-3.04%

1M Return-0.73%

Cost of sales ratio (%)

Value48.21

Score2/3

Weight-2.99%

1M Return-0.74%

Asset-MV

Value-0.55

Score1/3

Weight43.29%

1M Return7.28%

Is TEVA fundamentally strong?

TEVA scores 1.49/10 on fundamentals and holds a Premium valuation at present. Backed by its 2.07% ROE, 8.22% net margin, 234.37 P/E ratio, 4.18 P/B ratio, and 184.83% earnings growth, these metrics solidify its Underperform investment rating.